A review of secondary coronary prevention with dipyridamole and aspirin.
A large number of placebo-controlled trials of antiplatelet drugs have been carried out. A summary of the results of AMIS, CDP, ISIS-2, PARIS I and II and the Antiplatelet Trialists' Collaboration is presented. It is concluded that two fatal events and three non-fatal events will be averted for every 100 patients given a 2-year course of antiplatelet agents, starting promptly after myocardial infarction.